Comparative Pharmacology
Head-to-head clinical analysis: SULFATRIM SS versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFATRIM SS versus UROPLUS SS.
SULFATRIM-SS vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal synergy.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
1 double-strength tablet (160 mg trimethoprim / 800 mg sulfamethoxazole) orally every 12 hours for 10-14 days.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
SMX: 9-12 hours (increased in renal impairment); TMP: 8-11 hours (increased in renal impairment); both prolonged in elderly.
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Renal excretion of unchanged sulfamethoxazole (SMX) approximately 20%, trimethoprim (TMP) approximately 60%; biliary/fecal elimination minor (SMX <5%, TMP <10%).
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic